Jeong Sae-Im writing for Korea Biomedical Review reports that Kolon Life Science  has obtained US FDA IND approval to conduct a phase 1/2a clinical trial based on a gene therapy for neuropathic pain known as KLS-2031. Kolon Life Science’s KLS-2031 is targeting...